These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19442324)

  • 1. Left ventricular hypertrophy and renin-angiotensin system blockade.
    Cowan BR; Young AA
    Curr Hypertens Rep; 2009 Jun; 11(3):167-72. PubMed ID: 19442324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
    Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
    Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
    Dahlöf B
    J Hypertens Suppl; 1993 Apr; 11(3):S29-35. PubMed ID: 8315516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.
    Kjeldsen SE; Strand A; Julius S; Okin PM
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):487-92. PubMed ID: 16849902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats.
    Zhang Q; Kohara K; Qui HY; Hiwada K
    Am J Ther; 1997; 4(5-6):199-202. PubMed ID: 10423611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of renin-angiotensin blockade in patients receiving dialysis.
    Suzuki H
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):397-405. PubMed ID: 19491138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
    Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
    J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular hypertrophy--the problem and possible solutions.
    Gosse P
    J Int Med Res; 2005; 33 Suppl 1():3A-11A. PubMed ID: 16222895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
    Shimoura H; Tanaka H; Matsumoto K; Mochizuki Y; Hatani Y; Hatazawa K; Matsuzoe H; Ooka J; Sano H; Sawa T; Motoji Y; Ryo-Koriyama K; Hirata KI
    Heart Vessels; 2017 May; 32(5):584-590. PubMed ID: 27722772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.
    Le Corvoisier P; Adamy C; Sambin L; Crozatier B; Berdeaux A; Michel JB; Hittinger L; Su J
    Eur J Heart Fail; 2010 Nov; 12(11):1171-8. PubMed ID: 20870672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?
    Fleischmann EH; Schmieder RE
    Curr Cardiol Rep; 2002 Nov; 4(6):474-8. PubMed ID: 12379166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
    Major TC; Olszewski B; Rosebury W; Okerberg C; Carlson T; Ostroski R; Schroeder R; Kowala MC; Leadley R
    Cardiovasc Drugs Ther; 2008 Dec; 22(6):469-78. PubMed ID: 18679781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM
    Am J Med; 2008 Aug; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.